Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exendin-9,39 dose-response on food intake after gastric bypass
NCT02128581Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- May 2014
- Primary completion
- Mar 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of exendin 9-39 (3 arms), sponsored by Mayo Clinic. Primary endpoint: Calories consumed during buffet meal test at 300 minutes. Started May 2014; status: completed.
02
Drugs
exendin 9-39
Beyond the preview
Go deeper on NCT02128581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02128581.